Table 1 Basic characteristics and opioid dosage, palliative care drug usage of the home care group and the hospital care group
From: A comparison of opioid dose between home palliative care and hospital palliative care
Hospital group | Home care group | Overall | P-value | |
|---|---|---|---|---|
(n = 161) | (n = 48) | (n = 209) | ||
Age | 0.02* | |||
Mean (SD) | 70.1 (12.3) | 74.8 (12.1) | 71.2 (12.4) | |
Median [Q1, Q3] | 72.0 [64.0, 79.0] | 76.0 [66.8, 84.8] | 72.0 [64.0, 79.0] | |
Sex | 0.70** | |||
Female | 80 (49.7%) | 26 (54.2%) | 106 (50.7%) | |
Male | 81 (50.3%) | 22 (45.8%) | 103 (49.3%) | |
Serum Alb, ng/dl | 0.01* | |||
Mean (SD) | 2.32 (0.674) | 2.60 (0.611) | 2.38 (0.670) | |
Median [Q1, Q3] | 2.35 [1.80, 2.70] | 2.60 [2.10, 3.00] | 2.40 [1.90, 2.80] | |
Missing | ||||
Charlson Comorbidity Index | 0.50* | |||
Mean (SD) | 6.65 (2.52) | 6.38 (2.18) | 6.58 (2.44) | |
Median [Q1, Q3] | 7.00 [6.00, 8.00] | 6.00 [6.00, 8.00] | 7.00 [6.00, 8.00] | |
Palliative Prognosis Score | 0.32* | |||
Median [Q1, Q3] | 40.0 [30.0, 50.0] | 50.0 [30.0, 50.0] | 40.0 [30.0, 50.0] | |
Follow up period days | < 0.001* | |||
Median [Q1, Q3] | 20.0 [10.0, 32.0] | 40.0 [21.0, 66.0] | 22.0 [12.0, 41.0] | |
Conscinousness disturbance 14 days before death, % | < 0.001** | |||
Positive | 15 (9.3%) | 13 (27.1%) | 28 (13.4%) | |
Negative | 146 (90.7%) | 35 (72.9%) | 181 (86.6%) | |
Dyspnea 14 days before death, % | 0.01† | |||
Positive | 27 (16.8%) | 1 (2.1%) | 28 (13.4%) | |
Negative | 134 (83.2%) | 47 (97.9%) | 181 (86.6%) | |
Conscinousness disturbance 7 days before death, % | < 0.001** | |||
Positive | 21 (13.0%) | 22 (45.8%) | 43 (20.6%) | |
Negative | 140 (87.0%) | 26 (54.2%) | 166 (79.4%) | |
Dyspnea 7 days before death, % | 0.31† | |||
Positive | 36 (22.4%) | 7 (14.6%) | 43 (20.6%) | |
Negative | 125 (77.6%) | 41 (85.4%) | 166 (79.4%) | |
Maligncy types | 0.39† | |||
Blood | 12 (7.5%) | 3 (6.3%) | 15 (7.2%) | |
Breast | 8 (5.0%) | 2 (4.2%) | 10 (4.8%) | |
Gastrointestinal | 63 (39.1%) | 26 (54.2%) | 89 (42.6%) | |
Gynecology | 4 (2.5%) | 5 (10.4%) | 9 (4.3%) | |
Lung | 39 (24.2%) | 8 (16.7%) | 47 (22.5%) | |
Urology | 19 (11.8%) | 2 (4.2%) | 21 (10.0%) | |
Others | 16 (9.9%) | 2 (4.2%) | 18 (8.6%) | |
Oral morphine equivalent dose 14 days before death, mg/day | 0.32* | |||
Mean (SD) | 35.7 (102) | 53.0 (116) | 39.7 (105) | |
Median [Q1, Q3] | 0 [0, 30.0] | 15.0 [0, 40.0] | 0 [0, 30.0] | |
Non-steroidal anti-inflammatory drug usage 14 days before death, % | < 0.001** | |||
User | 29 (18.0%) | 21 (43.8%) | 50 (23.9%) | |
Non-user | 132 (82.0%) | 27 (56.3%) | 159 (76.1%) | |
Anti-psychotic drug usage 14 days before death, % | 0.01† | |||
User | 3 (1.9%) | 6 (12.5%) | 9 (4.3%) | |
Non-user | 158 (98.1%) | 42 (87.5%) | 200 (95.7%) | |
Continous intravnous sedation usage 14 days before death, % | 0.32† | |||
User | 3 (1.9%) | 2 (4.2%) | 5 (2.4%) | |
Non-user | 158 (98.1%) | 46 (95.8%) | 204 (97.6%) | |
Oral morphine equivalent dose 7 days before death, mg/day | 0.49* | |||
Mean (SD) | 57.7 (131) | 72.8 (142) | 61.2 (133) | |
Median [Q1, Q3] | 15.0 [0, 56.0] | 23.3 [0, 78.8] | 16.0 [0, 60.0] | |
Non-steroidal anti-inflammatory drug usage 7 days before death, % | 0.01** | |||
User | 32 (19.9%) | 18 (37.5%) | 50 (23.9%) | |
Non-user | 129 (80.1%) | 30 (62.5%) | 159 (76.1%) | |
Anti-psychotic drug usage 7 days before death, % | 0.07† | |||
User | 5 (3.1%) | 7 (14.6%) | 12 (5.7%) | |
Non-user | 156 (96.9%) | 41 (85.4%) | 197 (94.3%) | |
Continous intravnous sedation usage 7 days before death, % | 0.66† | |||
User | 5 (3.1%) | 2 (4.2%) | 7 (3.3%) | |
Non-user | 156 (96.9%) | 46 (95.8%) | 202 (96.7%) | |
Pain control failure between 7 and 14 days before death | 1.00† | |||
Positive | 10 (6.2%) | 3 (6.3%) | 13 (6.2%) | |
Negative | 151 (93.8%) | 45 (93.8%) | 196 (93.8%) | |